VENENUM BIODESIGN, LLC
8Patents
8Active
8Granted
44Portfolio score
Filing activity: Jun 8, 2017 → Jun 8, 2021
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10654834B2 | Non-systemic TGR5 agonists | Human Necessities | 2 | Active |
| US11161864B2 | Sting agonists | Human Necessities | 0 | Active |
| US11583538B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US11306098B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Human Necessities | 0 | Active |
| US10669242B2 | Clostridium difficile toxin inhibitors | Chemistry; Metallurgy | 0 | Active |
| US11883420B2 | Sting agonists for treating bladder cancer and solid tumors | Human Necessities | 0 | Active |
| US11110106B2 | Sting agonists for treating bladder cancer and solid tumors | Human Necessities | 0 | Active |
| US11236055B2 | Non-systemic TGR5 agonists | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.